Skip to main content

Table 5 Exploratory analysis on H-scores for stathmin, pS6, pMTOR and pAKT

From: Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response

Stathmin
H-scores Range: 0-300/300; Optimal Cut-off*: 15/300
H-scores: High vs. Low High H-scores (>15/300) Low H-scores (≤15/300)  
Disease stabilization rate** 7/21 (33%) 7/13 (46%) p = 0.238
OR for disease stabilization** 0.429 (95% CI 0.104-1.770) p = 0.242
AFP response*** 2/6 (33%) 6/16 (38%) p = 0.376
pS6
H-scores Range: 0-300/300; Optimal Cut-off*:120/300
H-scores: High vs. Low High H-scores (>120/300) Low H-scores (≤120/300)  
Disease stabilization rate** 8/17 (47%) 6/17 (35%) p = 0.489
OR for disease stabilization** 1.630 (95% CI 0.411-6.459) p = 0.487
AFP response*** 4/11 (36%) 4/11 (36%) p = 0.341
pMTOR
H-scores Range: 0-180/300; Optimal Cut-off*: 20/300
H-scores: High vs. Low High H-scores (>20/300) Low H-scores (≤20/300)  
Disease stabilization rate** 7/10 (70%) 7/24 (29%) p = 0.028
OR for disease stabilization** 5.667 (95% CI 1.129-28.454) p = 0.035
AFP response 4/16 (25%) 4/6 (67%) p = 0.085
pAKT
H-scores Range: 0-240/300; Optimal Cut-off*: 5/300
H-scores: High vs. Low High H-scores (>5/300) Low H-scores (≤5/300)  
Disease stabilization rate** 4/11 (36%) 10/23 (43%) p = 0.693
OR for disease stabilization** 0.743 (95% CI 0.169-3.262) p = 0.694
AFP response*** 7/16 (44%) 1/6 (17%) p = 0.215
  1. *H-scores Optimal Cut-off based on ROC.
  2. **Disease stabilization rate (CR + PR + SD) ≥12 weeks, number of patients available for analysis = 34; disease stabilization in association with H-scores were compared using Fisher’s exact and proportional hazard model.
  3. ***AFP response, number of patients available for analysis = 22; AFP drop in association with H-scores were compared using Fisher’s exact.